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To investigate a novel branch of the shikimate biosyn-
thesis pathway operating in the formation of 3-amino-5-
hydroxybenzoic acid (AHBA), the unique biosynthetic
precursor of rifamycin and related ansamycins, a series
of target-directed mutations and heterologous gene ex-
pressions were investigated in Amycolatopsis mediterra-
nei and Streptomyces coelicolor. The genes involved in
AHBA formation were inactivated individually, and the
resulting mutants were further examined by incubating
the cell-free extracts with known intermediates of the
pathway and analyzing for AHBA formation. The rifL,
-M, and -N genes were shown to be involved in the step(s)
from either phosphoenolpyruvate/D-erythrose 4-phos-
phate or other precursors to 3,4-dideoxy-4-amino-D-ar-
abino-heptulosonate 7-phosphate. The gene products of
the rifH, -G, and -J genes resemble enzymes involved in
the shikimate biosynthesis pathway (August, P. R.,
Tang, L., Yoon, Y. J., Ning, S., Mu ¨ller, R., Yu, T.-W., Tay-
lor, M., Hoffmann, D., Kim, C.-G., Zhang, X., Hutchinson,
C. R., and Floss, H. G. (1998) Chem. Biol. 5, 69–79). Mu-
tants of the rifH and -J genes produced rifamycin B at
1% and 10%, respectively, of the yields of the wild type;
inactivation of the rifG gene did not affect rifamycin
production significantly. Finally, coexpressing the
rifG–N and -J genes in S. coelicolor YU105 under the
control of the act promoter led to significant production
of AHBA in the fermented cultures, confirming that
seven of these genes are indeed necessary and sufficient
for AHBA formation. The effects of deletion of individual
genes from the heterologous expression cassette on
AHBA formation duplicated the effects of the genomic
rifG–N and -J mutations on rifamycin production, indi-
cating that all these genes encode proteins with cata-
lytic rather than regulatory functions in AHBA forma-
tion for rifamycin biosynthesis by A. mediterranei.
3-Amino-5-hydroxybenzoic acid (AHBA)
1 has been identified
as the common starter unit (mC7N unit) for the biosynthesis of
ansamycins (1–3) and mitomycins (4). Ansamycins are a class
of natural compounds produced by a variety of microorganisms
and plants and are characterized by a macrocyclic structure
consisting of an aromatic ring system connected to an aliphatic
chain that forms an amide linkage to the amino group of the
aromatic moiety (5). Based on the structure of the AHBA-
derived aromatic moiety, this family of compounds can be fur-
ther subdivided into a benzenic and a naphthalenic subgroup.
The benzenic ansamycins, such as geldanamycin, ansatrienin
A, and ansamitocin (Fig. 1), have been isolated from actinomy-
cetes or higher plants and are mainly cytotoxic agents against
eukaryotes (6–13). Naphthomycin, streptovaricin, rifamycin B,
and tolypomycin Y (Fig. 1) represent the naphthalenic ansamy-
cins and have antibacterial activity, particularly against Gram-
positive bacteria and Mycobacterium tuberculosis (14–19).
The biosynthesis of AHBA has been studied in organisms
producing various ansamycins and mitomycin C through the
incorporation of
13C- and
14C-enriched glucose, glycerate, and
other precursors. This work led to the hypothesis that the
seven-carbon mC7N unit is derived from the shikimate biosyn-
thesis pathway (20–23). Genetic investigations on aromatic
amino acid-deficient mutants of Amycolatopsis mediterranei
N813 further revealed that the mC7N unit of the rifamycin
chromophore must be derived from early intermediates of the
shikimate biosynthesis pathway (24–27). However, there has
never been success in any attempts to obtain incorporation of
labeled shikimic acid, quinic acid, or 3-dehydroquinic acid
(DHQ) into the mC7N unit (20, 23, 28–30).
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This paper is available on line at http://www.jbc.org 12546Based on our previous studies (31–33), we have proposed a
novel pathway for the formation of AHBA, which parallels the
early stages of the shikimate biosynthesis pathway (Fig. 1).
Nitrogen is introduced at the earliest biosynthetic step to form
an amino analog of 3-deoxy-D-arabino-heptulosonate 7-phos-
phate (DAHP). Proposed intermediates such as 3,4-dideoxy-4-
amino-D-arabino-heptulosonate 7-phosphate (aDAHP), 5-de-
oxy-5-amino-3-dehydroquinate (aDHQ), and 5-deoxy-5-amino-
3-dehydroshikimate (aDHS) were synthesized and shown to be
efficiently converted into AHBA in crude cell-free extracts of
the rifamycin B producer, A. mediterranei S699, and the ansa-
trienin A producer, Streptomyces collinus Tu ¨1892. However,
the normal shikimate biosynthesis pathway intermediate,
DAHP, did not seem to give rise to AHBA under the same
conditions, although phosphoenolpyruvate plus erythrose
4-phosphate were indeed converted into aDAHP and AHBA,
albeit in very low yield.
The enzyme which aromatizes aDHS to form AHBA has been
purified from A. mediterranei S699 (33). The encoding gene,
rifK, has been cloned, sequenced, and verified through gene
inactivation to be essential for the biosynthesis of the mC7N
unit of rifamycin (33). Along with the rifK gene, a region of 95
kb of DNA (Fig. 2) has been isolated and sequenced (34). This
revealed five large open reading frames (ORFs) coding for a
modular type I polyketide synthase, various putative modifying
and regulatory genes, and a subcluster of ORFs, the rifG--N
genes, some of which are homologous to genes involved in the
shikimate biosynthetic and quinate utilization pathways of
plants, bacteria and fungi (34). The rifG, -H, and -I genes,
encoding homologues of a DHQ synthase, a plant-type DAHP
synthase, and a shikimate or quinate dehydrogenase, respec-
tively, are located upstream of the rifK gene. Surprisingly, the
rifJ gene, which appears to encode a type II DHQ dehydratase
homologue, is located outside this subcluster about 26 kb down-
stream from the rifK gene. Presumably, the rifH product has a
similar enzymatic activity as DAHP synthase to condense
phosphoenolpyruvate and erythrose 4-phosphate in the forma-
tion of aDAHP. The formation of aDHQ and aDHS would be
expected to involve the rifG and -J products to catalyze the
cyclization and dehydration, respectively. The rifK product,
AHBA synthase, then aromatizes aDHS to AHBA. The pres-
ence of the rifI gene is curious, as it suggests that the inter-
conversion of aDHQ and 3-deoxy-3-aminoquinic acid or aDHS
and 5-deoxy-5-aminoshikimic acid might play a role in AHBA
formation.
The nitrogen of AHBA was originally proposed to originate
from the amide nitrogen of glutamine by action of an amidohy-
drolase (31). However, a subsequent
15N experiment did not
support this notion (32), and no homology to known amidohy-
drolases was seen in the entire rif cluster. The only gene
obviously related to nitrogen metabolism is orf9, located 11 kb
downstream of the rifK gene, which encodes an aminotrans-
ferase predicted to catalyze amination of a keto group to an
aminosugar (34). Curiously, there are four genes, rifL, -M, -N,
and -O, located immediately downstream of rifK, which are not
obviously shikimate pathway-related. RifO is homologous to
FIG.1 .Comparison of early biosyn-
thetic steps of the shikimate biosyn-
thesis pathway with the proposed
pathway for the formation of AHBA
(32, 33) (A) and AHBA-derived antibi-
otics (B).
Characterization of the AHBA Biosynthetic Genes 12547certain regulatory genes but its inactivation did not decrease
rifamycin B formation.
2 The gene product of rifL is similar to a
class of oxidoreductases that have been implicated in intercon-
versions between hydroxyl and carbonyl groups, such as glu-
cose-fructose oxidoreductase which oxidizes glucose to glucono-
lactone and reduces fructose to sorbitol in Zymomonas mobilis
(37). The deduced peptide sequence of the rifM gene has con-
siderable similarity with the CBBY family of phosphoglycolate
phosphatases involved in glycolate oxidation (38). The rifN
gene product shows a significant similarity with the glucose
kinase from Streptomyces coelicolor and Bacillus megaterium
involved in glucose repression (39, 40). In the context of the
current model of rifamycin biosynthesis, the observed homolo-
gies of the gene products of rifL, -M, and -N do not clearly
reveal their functions. However, the juxtaposition of the rifK
and rifL–N genes suggests that there is an organized subclus-
ter or a potential operon that may be responsible for AHBA
biosynthesis.
In the present study we have examined the involvement of
the rifG–N, orf9, and rifJ genes in AHBA formation. We de-
scribe inactivation experiments for each of these genes and the
biochemical characterization of the mutants generated. The
rifG–N and -J genes were further subcloned and coexpressed in
S. coelicolor YU105.
MATERIALS AND METHODS
Strains and Culture Conditions
All strains and plasmids used in this work are listed in Table I. A.
mediterranei S699 was a gift from Dr. G. C. Lancini (Lepetit S.A.,
Varese, Italy) and was grown as described previously (33). SM medium
was used for sporulation. The E. coli strain XL-1 Blue (Stratagene) was
routinely used as the host strain for DNA manipulations and for con-
structing the gene-inactivated suicide vectors. The strain was grown in
LB medium supplemented with carbenicillin (100 mg/ml) or hygromycin
(100 mg/ml). S. coelicolor YU105 served as the host for the coexpression
of the rifG–N and rifJ genes and was cultured in modified R5 medium
(without sucrose) (35).
DNA Manipulation and Analysis
The total genomic DNA of A. mediterranei was isolated as described
(33). Southern blotting analysis was carried out as described (33) or
using the DIG luminescent labeling and detection kit (Roche Molecular
Biochemicals). Oligonucleotides were obtained from Life Technologies,
Inc. PCR was carried out in a TEMPTRONIC thermal cycler (Ther-
molyne). General cloning procedures and manipulation of DNA were
performed according to Sambrook et al. (36). The gene sequence of the
rifamycin biosynthetic gene cluster, including rifG–O, has been depos-
ited at GenBanky under accession numbers AF040570 and AF040571.
Mutagenesis in A. mediterranei
A 1.7-kb DNA fragment carrying the hyg gene for hygromycin resist-
ance either from pIJ693 (41) or pIJ5607
3 was routinely used as the
selection marker in the generation of the gene-inactivated constructs.
The DNA fragments containing the targeted genes were subcloned into
pUC119 (43) or pBluescript SK(2) (Stratagene). The DNA fragments
containing the region to be mutated were as given below:
RifG Inactivation—A 3.8-kb XhoI fragment containing the rifG gene
was cloned into pBluescript II SK(2), cut at the unique AscI site on the
N terminus of the rifG gene, blunt-ended, and religated to create
pHGF7101. A new BssHII site was generated and led to a frameshift
mutation in the N terminus of the rifG gene. The replacement suicide
vector pHGF7102 was created by insertion of a 1.7-kb KpnI fragment
carrying the hygromycin resistance gene from pIJ5607 into KpnI-
treated pHGF7101.
RifG–I Inactivation—A 5.6-kb XhoI-SacI fragment containing the C
terminus of the rifE gene, the entire rifF–I genes and the N terminus of
the rifK gene, was cloned into pBluescript SK(2), partially digested
with NotI, and religated to create pHGF7206. A 2496-bp NotI fragment
carrying the C terminus of the rifG gene, the entire rifH gene, and the
N terminus of the rifI gene was deleted. The replacement suicide vector
pHGF7207 was created by the insertion of a 1.7-kb KpnI fragment
carrying the hygromycin resistance gene from pIJ5607 into KpnI-
treated pHGF7206.
RifI Inactivation—A 3.4-kb BsiWI-EcoRI fragment containing the
rifI gene was cloned into LITMUS 29 (New England Biolabs, New
England), cut at the unique XhoI site on the N terminus of the rifI gene,
blunt-ended, and religated to create pHGF7202. A new PvuI site was
generated and led to a frameshift mutation in the rifI gene. The re-
placement suicide vector pHGF7203 was created by the insertion of a
1.7-kb KpnI fragment carrying the hygromycin resistance gene from
pIJ5607 into KpnI-treated pHGF7202.
RifL Inactivation—The 1.6-kb EcoRI-XhoI and 1.65-kb XhoI-BamHI
fragments containing the N terminus and C terminus of the rifL gene,
respectively, were ligated and cloned into pHGF008 to create pRM04. A
624-bp XhoI fragment was deleted in the rifL gene. The replacement
2 R. Mu ¨ller and M. Taylor, unpublished results.
3 C. Khosla, personal communication.
FIG.2 .Genetic organization of the
rifamycin biosynthetic gene cluster.
The cluster is shown at two scales; the
upper scale shows the entire cluster (95
kb) and indicates five large ORFs coding
for the modular type I polyketide syn-
thase (rifA–E). Three regions (I–III) re-
vealed coding sequences, which are either
homologous to genes involved in the shiki-
mate biosynthetic and quinate utilization
pathways, or are implicated to be AHBA
pathway-related components. The orien-
tation of the arrows indicates the direc-
tion of each ORF. Lines indicate inserts of
plasmid clones. Ba, BamHI; K, KpnI; Bs,
BsiWI; As, AscI; X, XhoI; Ec, EcoRI; Sc,
SacI; Mu, MluI; Bsr, BsrGI; Bg, BglII.
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Bacterial strains and plasmids used in this study
Strains or plasmids Properties or product Source or reference
Strains
A. mediterranei S699 Wild type, rifamycin B G.C. Lancini, Lepetit S.A.
HGF003 rifK<hyg (33)
HGF005 XhoI site eliminated (filled-in) from rifI This study
HGF008 AscI site eliminated (filled-in) from rifG This study
HGF009 2.5-kb NotI fragment (rifG, rifH, and rifI) deleted This study
RM01 624-bp XhoI fragment deleted from rifL This study
RM04 MluI site eliminated (filled-in) from rifM This study
RM05 BsrGI site eliminated (filled-in) from rifN This study
MM01 897-bp PstI fragment deleted from orf9 This study
XZ01 BglII site eliminated (filled-in) from rifJ This study
S. lividans 1326 Wild type (35)
S. coelicolor YU105 (42)
Plasmids
pBluescript II SK(2) Phagemid vector derived from pUC19 GenBank™ no. X52329
pUC119 Phagemid vector derived from pUC19 (43)
pCR-Script Amp
SK(1)
Phagemid vector derived from pUC19 Stratagene
LITMUS 29 Multipurpose cloning/in vitro transcription phagemid vector New England Biolabs
pNEB193 pUC19 derivative that carries single sites for AscI, PacI, and PmeI New England Biolabs
pIJ963 hyg cassette in pUC18 (41)
pIJ4123 Thiostrepton-inducible His-tagged protein expression vector (54)
pIJ5607 hyg cassette in pUC18 See Footnote 3
pIJ6021 Thiostrepton-inducible expression vector (54)
pRM5 act expression vector (44)
pRM004 1.6-kb EcoRI-XhoI and XhoI-BamHI fragments containing the up- and
downstream of the rifL DNA stretch ligated and cloned into pHGF008, and
resulted in a 624-bp deletion in rifL.
This study
pRM005 1.7-kb KpnI hyg fragment from pIJ5607 cloned into pRM004 This study
pRM028 15.8-kb KpnI rif fragment cloned into pBluescript II SK(2) This study
pRM029 rifG expression vector This study
pRM031 MulI site eliminated from rifM in pHGF007 This study
pRM032 1.7-kb KpnI hyg fragment from pIJ5607 cloned into pRM031 This study
pRM035 1.7-kb KpnI hyg fragment from pIJ5607 cloned into pRM036 This study
pRM036 BsrGI site eliminated from rifN in pHGF007 This study
pRM041 1.1-kb PCR-generated fragment containing the N-terminal part of rifG cloned
into SrfI site of pCRScript
This study
pRM043 11.4-kb AscI-HindIII rif fragment from pRM028 cloned into pRM041 This study
pRM046 BglII site eliminated from rifJ in pHGF018 This study
pRM051 1.7-kb BglII hyg fragment from pIJ963 cloned into BamHI site of pRM046 This study
pRM084 1.1-kb NdeI-EcoRI fragment cloned from pRM029 into pIJ4123 This study
pRM086 1.1-kb NdeI-EcoRI fragment cloned from pRM029 into pIJ6021 This study
pHGF007 8.6-kb EcoRI-KpnI rif fragment cloned into pUC119 This study
pHGF008 neo cassette cloned into SrfI site of pCRScript P.R. August,
personal communication
pHGF010 3.8-kb BamHI-EcoRI rif fragment cloned into pUC119 This study
pHGF018 2.5-kb EcoRI-BamHI rif fragment cloned into pUC119 This study
pHGF102 897-bp PstI fragment (orf9) deleted from pHGF010 This study
pHGFAT108 1.7-kb BglII hyg fragment from pIJ963 cloned into BamHI site of pHGF102 This study
pHGF7100 3.8-kb XhoI rif fragment cloned into pBluescript II SK(2) This study
pHGF7101 AscI site eliminated from rifG in pHGF7100 This study
pHGF7102 1.7-kb KpnI hyg fragment from pIJ5607 cloned into pHGF7101 This study
pHGF7201 3.4-kb BsiWI-EcoRI rif fragment cloned into LITMUS 29 This study
pHGF7202 XhoI site eliminated from rifl in pHGF7201 This study
pHGF7203 1.7-kb KpnI hyg fragment from pIJ5607 cloned into pHGF7202 This study
pHGF7205 5.6-kb XhoI-SacI rif fragment cloned into pBluescript II SK(2) This study
pHGF7206 2.5-kb NotI fragment deleted from rif in pHGF7205 This study
pHGF7207 1.7-kb KpnI hyg fragment from pIJ5607 cloned into pHGF7206 This study
pHGF7406 rifK expression vector (45)
pHGF7409 8.6-kb EcoRI-HindIII fragment cloned from pRM028 into pHGF7406 This study
pHGF7414 0.5-kb NcoI-HindIII fragment that was generated by PCR and carries the
whole rifJ, cloned into pHGF7409 to replace the 0.84-, 2.3-, and 1.4-kb NcoI
and NcoI-HindIII fragments
This study
pHGF7501 3.1-kb PacI-HindIII fragment cloned from pRM5 into pNEB193 This study
pHGF7502 NdeI site eliminated from lacZ in pHGF7501 This study
pHGF7503 Described under “Materials and Methods” This study
pHGF7504 4.5-kb NdeI-XbaI fragment cloned from pHGF7414 into pHGF7503 This study
pHGF7505 A pNEB193-based actII-orf4/pactIII-actI cassette vector This study
pHGF7603 3.4-kb PacI-EcoRI fragment cloned from pRM043 into pRM5 This study
pHGF7604 6.0-kb PacI-HindIII fragment cloned from pHGF7504 into pHGF7603 This study
pHGF7605 3.4-kb PacI-BstBI (rifG, rifH, and rifI) fragment deleted from pHGF7604 This study
pHGF7606 AscI site eliminated from rifG in pHGF7604 This study
pHGF7607 624-bp XhoI fragment deleted from rifL in pHGF7604 This study
pHGF7608 224-bp ApaI fragment deleted from rifM in pHGF7604 This study
pHGF7609 832-bp NcoI-PmlI rifN containing fragment deleted in pHGF7604 This study
pHGF7610 505-bp NcoI-SpeI rifJ containing fragment deleted in pHGF7604 This study
pHGF7611 0.8-kb XhoI-EcoRI rifI containing fragment deleted in pHGF7605 This study
pHGF7612 0.8-kb XhoI-EcoRI rifI containing fragment deleted in pHGF7604 This study
pHGF7613 2.4-kb PacI-BstBI rifG, rifH, and rifI containing fragment deleted in
pHGF7604
This study
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fragment carrying the hygromycin resistance gene from pIJ5607 into
KpnI-treated pRM04.
RifM Inactivation—An 8.6-kb EcoRI-KpnI fragment containing the
rifM gene was cloned into pUC119, cut at the unique MluI site on the
N terminus of the rifM gene, blunt-ended, and religated to create
pRM031. A new BssHII site was generated and led to a frameshift
mutation in the rifM gene. The replacement suicide vector pRM032 was
created by the insertion of a 1.7-kb KpnI fragment carrying the hygro-
mycin resistance gene from pIJ5607 into KpnI-treated pRM031.
RifN Inactivation—An 8.6-kb EcoRI-KpnI fragment containing the
rifN gene was cloned into pUC119, cut at the unique BsrGI site on the
N terminus of the rifN gene, blunt-ended, and religated to create
pRM036. A new BsaAI site was generated and led to a frameshift
mutation in the rifN gene. The replacement suicide vector pRM035 was
created by insertion of a 1.7-kb KpnI fragment carrying the hygromycin
resistance gene from pIJ5607 into KpnI-treated pRM036.
RifJ Inactivation—A 2.5-kb BamHI-EcoRI fragment containing the
rifJ gene was cloned into pUC119, cut at the unique BglII site on the N
terminus of the rifJ gene, blunt-ended, and religated to create pRM046.
A new ClaI site was generated and led to a frameshift mutation in the
rifJ gene. The replacement suicide vector pRM051 was created by the
insertion of a 1.7-kb BglII fragment carrying the hygromycin resistance
gene from pIJ963 into BglII-treated pRM046.
Orf9 Inactivation—A 3.8-kb BamHI-EcoRI fragment containing the
orf9 gene, was cloned into pUC119, digested with PstI, and religated to
create pHGF102. An 897-bp PstI fragment was deleted in the orf9 gene.
The replacement suicide vector pHGFAT108 was created by the inser-
tion of a 1.7-kb BglII fragment carrying the hygromycin resistance gene
from pIJ963 into BglII-treated pHGF102.
The mycelia of A. mediterranei S699 were cultured to an early log-
phase in a 500-ml Erlenmeyer flask with springs containing 100 ml of
YMG medium, harvested by centrifugation, and washed twice with
ice-cold 10% glycerol. The prepared mycelia could be stored at 280 °C
for at least 6 months. The DNA replacement vectors (;2 mg) were
heat-denatured, immediately cooled on ice, and then used for transfor-
mation via electroporation. The transformed mycelia were transferred
directly into 60 ml of YMG medium and grown at 28 °C for 16–36 h to
increase the chance for homologous recombination between the intro-
duced vectors and the chromosomal DNA in growing mycelia. Regen-
erated mycelia were then plated onto YMG agar plates containing
hygromycin (100 mg/ml) and continually grown for 1–2 weeks. Inte-
grated transformants start to appear as visible colonies after 3 days.
The colonies resulting from the single crossover recombination were
plated on nonselective SM medium and screened for hygromycin-sen-
sitive recombinants derived from a second crossover event, through
which the vector with the resistance marker is excised. A dilution series
of the harvested spores was prepared and plated again on nonselective
YMG agarose plates. After a sufficient growth, these colonies were
replicated to YMG agarose plates containing hygromycin. Colonies
growing on the nonselective, but not the selective, agar plates were
isolated, and their total genomic DNA was prepared and analyzed by
Southern blotting to determine whether the rif genes had been replaced
with their corresponding inactivated versions or the colony was a re-
vertant to the wild type. Typically, 10–20 transformants were picked in
the initial gene disruption step. On average, 0.5–5% of gene replace-
ment clones are obtained with this procedure depending on the length
of DNA provided for homologous recombination.
AHBA Feeding and Rifamycin B Analysis
Cultures of the mutants were grown until they reached the early
stationary stage, split equally into two portions, and then transferred
into a new flask. AHBA (1–10 mg) was added to one of the cultures. The
cultures were then grown for 4 more days. The culture broths were
acidified with 1 N HCl to pH 2–3 and extracted twice with equal volumes
of ethyl acetate. After drying and removal of the organic solvent in a
vacuum, the residue was dissolved in 1 ml of methanol and analyzed by
HPLC (System GOLD, Beckman). HPLC was performed on an RP-18
column (250 3 4.6 mm, gradient MeOH:0.05% HOAc at t0m i n5 30:70,
at t20 min 5 100:0; 1.0 ml/min flow rate) with detection at l 5 256 and
425 nm. Rifamycin B tret 5 12.5 min. The eluted rifamycin B samples
were collected, and their identity was confirmed by electrospray-mass
spectrometry analysis.
The Vector for Expression of the rif Genes in S. coelicolor YU105
The actII-orf4/pactIII-actI Promoter Cassette—A 3.1-kb HindIII-
PacI fragment containing the divergent promoters (pactIII-actI) and the
regulatory gene (actII-orf4) from pRM5 (44) was cloned into pNEB193
(New England Biolabs). The unique NdeI site on the lacZ gene in
pNEB193 was then cut, blunt-ended, and eliminated to generate
pHGF7502. To introduce unique DNA cloning sites to increase the
cloning capacity and to eliminate nonessential sequences, two further
steps were carried out. First, a pair of oligomers, TIN004 and TIN005
(Table II), were annealed and cloned into HindIII-SacI-treated
pHGF7502 to replace the redundant HindIII-SacI fragment and incor-
porate BglII and PmeI sites upstream of actII-orf4 to generate
pHGF7503. Further, using pHGF7503 as the DNA template, two sep-
arate PCR reactions were performed. The PCRI mixture contained
oligomers TIN006 and M13–40 (Table II) as primers to obtain a 260-bp
DNA fragment containing the pactIII-actI promoter region. The PCRII
mixture used oligomers TIN001 and TIN007 (Table II), resulting in a
product with the 1.1-kb fragment carrying the whole actII-orf4 gene.
After treatment with XbaI, the products of PCRI and PCRII were
assembled, digested with HindIII and EcoRI, and cloned into
pHGF7503 to introduce the modified actII-orf4/pactIII-actI DNA frag-
ment, leading to pHGF7505. The sequence of the 1.4-kb HindIII-EcoRI
assembled product (Fig. 3) was confirmed, using an Applied Biosystems
model 377 sequencer.
Coexpressing rif Genes—An 8.6-kb EcoRI-HindIII fragment contain-
ing the C terminus of the rifK gene and the whole rifL–N genes from
pRM028 (Table I) was cloned into pHGF7406 and replaced the 1.6-kb
EcoRI-HindIII fragment (45) to create pHGF7409. Using pHGF018
(Table I) as the DNA template and primers TIN010 and TIN011, a
0.5-kb PCR product containing the whole rifJ gene was amplified and
cloned into pHGF7409 to replace the 4.6-kb NcoI-HindIII DNA frag-
ment located downstream of the rifN gene. The 4.5-kb NdeI-XbaI frag-
ment carrying the whole rifK–N and -J genes from the resulting con-
struct, pHGF7414, was further relocated to pHGF7505 to generate
pHGF7504. To introduce the PacI cloning site in front of the rifG gene,
a 1.1-kb PCR product containing the N-terminal part of rifG was gen-
erated using the DNA template, pHGF7100 (Table I), and primers
RM021 and RM024 (Table II). The resulting PCR product was sub-
cloned into pCRScript digested with SrfI, and then the 0.5-kb AscI-
HindIII fragment was further replaced with the 11.4-kb AscI-HindIII
fragment from pRM028 (Table I) to create pRM043. The 3.4-kb PacI-
EcoRI fragment carrying the rifG–I genes from pRM043 and the 6.0-kb
PacI-HindIII fragment carrying the rifK–N, rifJ, actII-orf4 genes and
pactI-III promoters from pHGF7504 were sequentially cloned into
TABLE II














Characterization of the AHBA Biosynthetic Genes 12550pRM5 to replace the resident act genes. The resulting construct was
designated pHGF7604 (Fig. 4).
pHGF7604-derived Constructs—To examine the functional activities
of the rif genes in pHGF7604, the coding region of each individual gene
was partially deleted or modified by the elimination of a unique restric-
tion site. First, the unique AscI site on the N terminus of the rifG gene
in pHGF7604 was cut, blunt-ended, and religated to generate
pHGF7606. This created a new BssHII site and led to a frameshift
mutation in the rifG gene. pHGF7607 and pHGF7608 were constructed
directly from pHGF7604 by the deletion of a 624-bp XhoI or a 224-bp
ApaI fragment located in the rifL and rifM coding regions, respectively.
The 832-bp NcoI-PmlI fragment covering the C terminus of the rifN
gene and the 505-bp NcoI-SpeI fragment containing the entire rifJ
coding region, respectively, were deleted in pHGF7604 by double cut-
ting with NcoI and PmlI, or SpeI, blunt-ending and religation to form
pHGF7609 and pHGF7610. Using the same strategy, the 0.8-kb XhoI-
EcoRI fragment containing the coding region of the rifI C terminus was
removed from pHGF7604 and pHGF7605, to create pHGF7612 and
pHGF7611, respectively. pHGF7613 was constructed from pHGF7604
by the elimination of the 2.4-kb PacI-BstBI fragment carrying the
coding sequences of the rifG–I genes.
Assay for AHBA Production
The AHBA produced in the bacterial cultures was detected through
the ability to restore rifamycin B production to the AHBA nonproducing
rifK mutant, A. mediterranei HGF003 (33). First, A. mediterranei
HGF003 and the test bacterial strains were grown separately in YMG
medium and the modified R5 medium (without sucrose) (35). When the
cultures had reached the stationary phase, the HGF003 and the test
cultures were mixed ina3t o1ratio and culturing was continued for 3
more days. The mixed cultures were then harvested and analyzed for
rifamycin B production by HPLC.
AHBA production was assayed quantitatively by the inverse isotope-
dilution procedure described by Kim et al. (32). In general, 40 mgo f
[7-
13C]AHBA (90%
13C) was added to the crude S. coelicolor cell extract
(2.5 ml), which was then silylated using 100 ml of SIGMA-SIL-A. The
gas chromatography mass spectrometry analysis was carried out on a
Hewlett Packard 5890 gas chromatograph connected to a Hewlett Pack-
ard 5971A mass selective detector under conditions as described previ-
ously (32). Enzymatic AHBA formation in cell-free extracts of A. medi-
terranei mutants was assayed as described by Kim et al. (32).
RESULTS
Effects of rifG, rifH, and rifI Genes on Rifamycin B Produc-
tion—Based on DNA and deduced peptide sequence analysis,
the products of rifG and rifH are homologous to a DHQ syn-
thase and a plant-type DAHP synthase involved in the shiki-
mate biosynthetic pathway, respectively. The rifI gene product
is similar to a shikimate or quinate dehydrogenase in the
shikimate biosynthesis and quinate utilization pathways in
bacteria, plants, and fungi. These three genes are located side
by side and immediately upstream of rifK, the AHBA synthase
gene. To relate their functions to AHBA biosynthesis, we con-
structed a mutant of A. mediterranei, HGF009, in which a
2496-bp NotI DNA fragment carrying the C terminus of rifG,
FIG.4 .The vector pHGF7604. The plasmid is bifunctional with the
ColE1 replication origin (oriC) and b-lactamase (bla) gene for selection
in E. coli, and SCP2* origin of replication and thiostrepton resistance
gene (tsr) for selection in Streptomyces. The cloned AHBA biosynthetic
genes to be expressed in S. coelicolor YU105 are inserted downstream of
pactIII (rifK–N, rifJ) and pactI( rifG–I), respectively, which are tran-
scriptionally activated by the product of the actII-orf4 gene. The de-
tailed procedure for this construction is described under “Materials and
Methods.”
FIG.3 . Nucleotide sequence of the
1486-bp HindIII-EcoRI insert carry-
ing the entire regulatory gene, actII-
orf4, and the modified pactIII-actI
promoters (accession no. AF335989)
in pHGF7505. The deduced actII-orf4
gene product is indicated in single-letter
code under the DNA sequence. Long ar-
rows indicate sequences showing inverted
repeat symmetry, which are putatively
associated with termination or attenua-
tion. The 210 and 235 regions of the
identified pactIII-actI promoters and the
actII-orf4 product binding sites (47) are
underlined and outlined, respectively.
The transcription start points of actI and
actIII are also indicated by short arrows.
Characterization of the AHBA Biosynthetic Genes 12551the entire rifH, and the N terminus of rifI had been deleted
from the genome. The mutant construction showed that there
is an endogenous promoter located upstream of rifG since all
isolated primary tranformants that arose by the expected sin-
gle-crossover integration either upstream of rifG or down-
stream of rifI had maintained the ability to produce a normal
amount of rifamycin B (data not shown). HGF009 is able to
grow on SM medium and produces rifamycin B, but HPLC
analysis showed that the yield has decreased to 1–2% of that of
the wild type strain S699 (Table III). Full rifamycin B produc-
tivity can be restored by supplementation of the culture with
AHBA.
To further examine the functional role of each of the three
genes in rifamycin biosynthesis individually, A. mediterranei
mutants HGF005 and HGF008 were constructed. In both
HGF005 and HGF008, four additional nucleotides were intro-
duced either at the unique XhoIo rAscI site, resulting in
frameshift mutations at the N terminus of the rifI and rifG
genes, respectively (see “Materials and Methods”). Both mu-
tants show a similar growth rate, either in SM or YMG me-
dium, as the wild type strain S699. Neither the truncation of
the rifI gene in HGF005 nor that of the rifG gene in HFG008
causes a significant change, if any, in the production of rifamy-
cin B compared with the wild type strain S699 (Table III).
Thus, the reduced rifamycin production by mutant HGF009
must be due largely to the absence of rifH.
The Products of rifL, rifM, and rifN Genes Are Essential for
AHBA Formation—Located downstream of the rifK gene are
three other genes, rifL, rifM, and rifN, that form a subcluster
and potentially an operon sharing a transcription unit starting
at rifK or possibly earlier (33, 34). The rifL gene encodes a
359-amino acid protein (37.91 kDa), and its initiation codon
appears to be located 73 bases downstream of the rifK gene. To
probe the function of the rifL product in AHBA and rifamycin
B biosynthesis, the replacement vector pRM05 (see “Materials
and Methods”) was transformed and integrated into A. medi-
terranei S699. Mutant RM01, in which a 624-bp XhoI DNA
fragment has been deleted from the rifL gene, was isolated
after a serial screening for the loss of resistance to hygromycin.
RM01 is unable to produce rifamycin B, but production can be
restored to wild type levels by supplementation of the culture
with AHBA (Table III).
The rifM gene encodes a 232-amino acid protein (24.84 kDa)
and is located 14 bases downstream of rifL, and 34 bases
upstream of the rifN gene, which codes for a 293-amino acid
protein (29.78 kDa). The mutants RM04 and RM05 carry the
inactivated rifM and rifN genes, respectively, in which four
additional nucleotides were introduced at the unique MluIo r
BsrGI site, leading to a frameshift mutation in the N terminus
of rifM and rifN, respectively. As observed above with RM01,
there is no detectable rifamycin B production in either mutant
and AHBA supplementation restores rifamycin B productivity
to wild type levels (Table III). Incubation of the crude cell-free
extracts of the mutants with the known pathway intermedi-
ates, aDAHP, aDHQ, or aDHS, showed that both the RM04 and
RM05 strains were able to convert aDAHP to AHBA with
efficiency comparable to that of the wild-type strain S699 (Ta-
ble III). However, cell-free extracts of strain RM01 failed to
convert aDAHP or aDHQ into AHBA, and gave only poor con-
version of aDHS, 10% compared with about 90% for the wild-
type strain (32).
The rifJ Gene Is Involved in Rifamycin B Biosynthesis—The
rifJ gene is located 26 kb downstream of the rifK gene (Fig. 2).
The deduced peptide it encodes is closely related to type II DHQ
dehydratases found in the biosynthetic shikimate and the
quinate utilization pathways. rifJ is likely to be part of the
rifamycin biosynthetic gene cluster, since rpoB and rpoC, genes
coding for the DNA-dependent RNA polymerase b- and b9-
subunits respectively, have been located 2.3 kb downstream of
the rifJ gene (34). The product of the rpoB gene was shown to
confer resistance to high doses of rifamycin B or rifampicin
when transferred to E. coli and Mycobacteria.
4 As antibiotic
biosynthetic gene clusters in Actinomycetes typically include
one or more genes that confer resistance to the antibiotic pro-
duced, the rif gene cluster is assumed to extend to the rpo
genes, and thus include rifJ. The rifJ gene product may cata-
lyze the conversion of aDHQ to aDHS through the elimination
of a water molecule.
To probe for the involvement of rifJ in AHBA formation, the
rifJ-inactivated suicide vector pRM051 (see “Materials and
Methods”) was introduced and integrated into A. mediterranei
S699. After serial propagation in hygromycin-free YMG me-
dium, the rifJ-inactivated mutant XZ01 was isolated. In it the
functional rifJ gene has been replaced with a mutated version
carrying four additional bases, GATC, at the unique BglII site,
which causes a frameshift mutation at the N terminus. The
elimination of rifJ does not abolish antibiotic production in the
XZ01 strain completely, but results in a reduction to ;10% of
the wild type level (Table III). Full rifamycin B production can
be restored by supplementation with AHBA (Table III). Mutant
XZ01 shows similar growth rates in SM and YMG media as the
wild type strain S699.
No Detectable Effect of the orf9 Gene on Rifamycin B Produc-
tion—The gene product of the orf9 gene is related to a dNTP-
hexose aminotransferase and has been proposed to be respon-
sible for the formation of an aminodeoxyhexose nucleotide (34).
However, since no glycosylated rifamycin has been identified in
the cultures of A. mediterranei S699, one cannot exclude the
possibility that this gene product might play a role in the
introduction of the amino group in the AHBA biosynthetic
pathway. Thus, the orf9-inactivated suicide vector pHG-
FAT108 was constructed (see “Materials and Methods”) and
introduced into A. mediterranei S699. After serial culturing,
the orf9 gene was then replaced through a second homologous
recombination with the truncated version in which an 897-bp
PstI DNA fragment has been deleted. The resulting mutant
MM01 showed no significant phenotypic change in either the
growth pattern or rifamycin B production (Table III).
Production of AHBA in S. coelicolor—The actII-orf4 gene
product has been characterized as a DNA-binding protein that
positively regulates the transcription of the actinorhodin bio-
synthetic genes in S. coelicolor (46, 47). The actIII-actI inter-
genic region, as the regulatory target for the actII-orf4 protein,
4 E. Pogosova-Agadjanyan and T.-W. Yu, unpublished data.
TABLE III
Characters of A. mediterranei S699-derived rif mutants and their
effects on rifamycin productivity
Strains Gene(s) inactivated Rifamycin
production
a Restored by AHBA
supplementation
%
HGF003 rifK 0 1
HGF005 rifI 100 Not tested
HGF008 rifG 100 Not tested
HGF009 rifG, rifH, rifI 1–2 1
RM01 rifL 0 1
RM04 rifM 0 1
RM05 rifN 0 1
MM01 orf9 100 Not tested
XZ01 rifJ 10 1
a The relative rifamycin production levels were compared with the
yield obtained from fermented cultures of A. mediterranei S699 wild-
type. 100% indicates that the yield is the same as or close to the
wild-type levels, and 0 stands for not detectable.
Characterization of the AHBA Biosynthetic Genes 12552carries a pair of divergently arranged promoters for the early
biosynthetic steps to build the polyketide backbone of actinor-
hodin. The development of a regulatory expression system em-
ploying the transcription regulator (the actII-orf4 gene prod-
uct) and the pathway-specific promoters (pactIII-actI) has
already served to generate many novel products of aromatic
and macrolide polyketide synthases (44, 48, 49). To verify the
functional specificity for each candidate gene in the AHBA
biosynthetic pathway, a pNEB193-based actII-orf4/pactIII-actI
cassette vector, pHGF7505, was constructed (see “Materials
and Methods”). This actII-orf4/pactIII-actI promoter cassette
(Fig. 4) with different multiple cloning sites allows for cloning
of the target genes to be regulated by a pactIo rp actIII pro-
moter for tight transcriptional control. The putative AHBA
biosynthetic genes defined as described above are located at
two separate regions of the rif gene cluster and may be orga-
nized into three separate transcription units (Fig. 2). The
0.5-kb NcoI-HindIII PCR-amplified DNA fragment carrying
the entire rifJ gene and a putative ribosome binding site,
GGAGG, was connected to the NcoI site, 64 bases downstream
of the stop codon of the rifN gene. As described under
“Materials and Methods,” the fused 4.5-kb NdeI-XbaI DNA
fragment containing the rifK–N and rifJ genes, and the 3.4-kb
PacI-EcoRI DNA fragment carrying the rifG–I genes, were
relocated into the actII-orf4/pactIII-actI promoter cassette at
the corresponding restriction sites. The resulting E. coli-Strep-
tomyces shuttle vector pHGF7604, which carries the actII-orf4
regulatory gene and eight rif genes (rifG–N and -J) under the
control of the pactIII-actI promoters, was then transformed
into S. coelicolor YU105. Unlike S. coelicolor YU105, which is
unable to produce AHBA or AHBA-derived ansamycins, S.
coelicolor YU105/pHGF7604 transformants can restore rifamy-
cin B production in the AHBA nonproducing rifK mutant, A.
mediterranei HGF003, and they produce a significant amount
of AHBA (350–400 mg/liter of culture) (Table IV).
AHBA Production Is Repressed by the Presence of the rifI
Gene—The specific functional roles of the rif genes in
pHGF7604 in AHBA formation were further examined in S.
coelicolor YU105. First, individual rif genes were removed from
pHGF7604 by deleting a region of the DNA fragment or by
eliminating restriction sites. The resulting nine new con-
structs, pHGF7605 to pHGF7613 (Table I), were then trans-
formed into S. coelicolor YU105 to assay for AHBA production.
Table IV summarizes the rif gene compositions and the AHBA
yields of pHGF7604 and the nine pHGF7604-derived con-
structs in S. coelicolor YU105. There was no AHBA detectable
in the three cultures of S. coelicolor YU105 transformed with
pHGF7607, pHGF7608, or pHGF7609. These results are con-
sistent with those from the corresponding three genomic mu-
tants of A. mediterranei, rifamycin-deficient strains RM01, -04,
and -05, and confirm that the rifL, -M, and -N gene products
are indeed absolutely essential for the formation of AHBA.
As mentioned above, A. mediterranei HGF008 and HGF005,
the rifG- and rifI-knockout mutants, did not show a significant
change in rifamycin B production compared with the wild type.
However, the absence of these genes from the AHBA gene
cassette clearly changes the AHBA production profile in S.
coelicolor YU105. Reproducibly, 20–25% more AHBA is de-
tected in the cultures transformed with pHGF7612, lacking the
rifI gene, than in those carrying pHGF7604. Removal of the
product of the rifI gene is not detrimental but seems to enhance
AHBA production. In contrast, the product of the rifG gene
plays a significant role in maintaining the AHBA productivity
in S. coelicolor YU105, since the yield decreased to only 10% in
the cultures of pHGF7606 transformants. These opposing ef-
fects are further confirmed by the moderate yields detected in
the cultures of transformants with pHGF7611, in which both
the rifG and rifI genes have been removed.
Deletion of the rifH gene causes a similarly severe effect on
AHBA production in S. coelicolor YU105 as on the production
level of rifamycin B in A. mediterranei seen in mutant HGF009.
The pHGF7605 transformants, in which both the rifH and rifI
genes have been deleted, produce less than 0.2% of the amount
of AHBA of the pHGF7612 transformants which lack only the
rifI gene. When the rifG gene is also removed, AHBA produc-
tion is completely abolished in cultures of the pHGF7605
transformants.
Eliminating the product of the rifJ gene decreases the yield
of AHBA to 6–8% in the cultures of the pHGF7610 transfor-
mants. This result is comparable to the one observed with the
genomic rifJ mutant, A. mediterranei XZ01, which lost about
90% of its rifamycin B productivity.
DISCUSSION
The biosynthesis of AHBA has been investigated through
target-directed mutagenesis in A. mediterranei S699 and het-
erologous expression in S. coelicolor YU105 of specific genes
from the rifamycin biosynthetic gene cluster. Three genes ho-
mologous to shikimate biosynthesis pathway genes, the rifG,
-H, and -J genes, and four not shikimate pathway-related
genes, the rifK (33), -L, -M, and -N genes, were identified as
being necessary and sufficient for AHBA formation. The obser-
vation that all these genes were required for AHBA production
in the heterologous host when expressed under the control of
an external promoter/regulator system suggests that none of
these genes have a regulatory function in AHBA formation by
the natural producer, A. mediterranei. Rather, all of them
should encode proteins with catalytic functions in the biosyn-
TABLE IV





rifG rifH rifI rifK rifL rifM rifN rifJ
mg/liter
pHGF7604 111 11111 350–400
pHGF7612 112 11111 450–500
pHGF7606 211 11111 30–40
pHGF7611 212 11111 150–200
pHGF7613 122 11111 , 1
pHGF7605 222 11111 0
b
pHGF7607 111 12111 0
b
pHGF7608 111 11211 0
b
pHGF7609 111 11121 0
b
pHGF7610 111 11112 20–30
a Cultures were grown in 60 ml of modified R5 medium for 1 week and worked up as described under “Materials and Methods.” The values are
typical of those obtained in five different fermentations.
b Not detectable.
Characterization of the AHBA Biosynthetic Genes 12553thetic pathway. The requirement for seven proteins for AHBA
formation, particularly the involvement of the rifL, -M, and -N
gene products, points to a degree of complexity of the pathway
not predicted by our previous hypothesis.
Functions of the rifG, rifH, and rifJ Gene Products—The
products of the rifG, -H, and -J genes have been shown to be
functionally active and, as predicted by our original hypothesis,
to play a key role in providing the substrate aDHS for AHBA
formation in the rifamycin producer, A. mediterranei S699. It is
worth noting that all three mutants, HGF005, -8, and -9,
showed no detectable growth defects in both the YMG and SM
media. This implies that the products of the rifG, -H, and -J
genes are probably not directly involved in any other, essential
shikimate pathway-related metabolic processes in the cell. The
fact that all three mutants kept producing rifamycin B at some
level suggests that the defects in rifamycin production caused
by the gene inactivations can be at least in part functionally
compensated by the presence of the corresponding shikimate
pathway isoenzymes in the strain, due to some overlap in
substrate specificity. For example, the DHQ synthase from E.
coli can cyclize aDAHP to produce aDHQ (32). The heterolo-
gously expressed RifG protein from S. lividans 1326 catalyzes
the cyclization of DAHP as well as aDAHP as substrate.
5 We
have detected and partially purified a second type II DHQ
dehydratase, a homologue of the rifJ gene product, from A.
mediterranei S699 (50). Recently, two additional DAHP syn-
thase isoenzymes and their encoding genes have been identi-
fied and cloned from A. mediterranei.
6 Interestingly, one of the
deduced peptide sequences is closely related to the product of
the rifH gene and to type II DAHP synthases from higher
plants.
The functional substitution and cross-talk between the prod-
ucts of the rifG, -H, and -J genes, and their corresponding
normal shikimate pathway homologues also occurred in the
expression of the rif genes to form AHBA in S. coelicolor
YU105. However, judging from the amounts of AHBA and
rifamycin B produced (Tables III and IV), it is evident that the
isoenzymes from S. coelicolor YU105 and from A. mediterrainei
S699 display different levels of competence to replace the func-
tions of the rifG, -H, and -J gene products. Notably, and per-
haps significantly, in both systems, the complementation of the
rifH mutation by endogenous DAHP synthases is less efficient.
It is not clear whether the greater competence for complemen-
tation observed in the A. mediterranei mutants is accidental or
has evolved due to a long term molecular adaptation between
substrates and the enzymes exposed to the rifamycin-produc-
ing environment.
Functional Role of the rifI Product—Although its functional
role is not obvious, the presence of the rifI gene in the rif gene
cluster of A. mediterranei S699 is unlikely to be an evolutionary
accident. First, the recombinant protein expressed from the rifI
gene in E. coli had the ability to catalyze the 3-dehydrogenation
of shikimate, aminoshikimate, and aminoquinate, but not
quinate (51). The present work showed that AHBA production
in S. coelicolor YU105 was significantly repressed by the pres-
ence of the rifI gene in the expression vectors, pHGF7604 and
-6 (Table IV). Since the rifI gene is part of the same transcrip-
tion unit as the rifG and rifH genes, it should be functionally
expressed and produce enzymatically active protein in A. medi-
terranei S699; yet, its disruption had no effect on rifamycin B
production. This result recalls the previous observation (32)
that there is no increase in the production of rifamycin B by
supplementation of wild-type A. mediterranei S699 with
AHBA, suggesting that rifamycin B synthesis in the cell is not
limited by the production of AHBA.
The earlier AHBA feeding experiments had indicated that
AHBA is very stable in the cells of A. mediterranei and is
maintained throughout the whole fermentation process with-
out substantial degradation. It is not known whether the accu-
mulation of AHBA could lead to inhibition or suppression of
regular shikimate pathway-related enzyme functions or cause
any other cellular toxicity, but this possibility might provide an
explanation for the presence of the rifI gene. The product of the
rifI gene may act in the conversion of aDHQ and/or aDHS to
3-deoxy-3-aminoquinic acid and/or 5-deoxy-5-aminoshikimic
acid, and closely regulate an AHBA-precursor reservoir to pre-
vent the uncontrolled accumulation of AHBA in the cell.
Functions of the Products of the rifL, rifM, and rifN
Genes—As the enzyme AHBA synthase (the product of the rifK
gene) described previously (33), the products of the rifL, -M,
and -N genes are also absolutely essential for the biosynthesis
of AHBA, yet they are not related to any shikimate pathway
enzymes. It is noteworthy that the location and arrangement of
all AHBA synthase genes identified relative to other genes
involved in AHBA biosynthesis in their respective gene clusters
varies (34, 52, 53).
7 However, the close association between the
AHBA synthase gene and the rifL and -M gene homologues is
conserved in all the AHBA biosynthesis gene clusters analyzed.
This suggests that there are functional interactions between
these gene products. The results of the cell-free experiments
with the rifL, -M, and -N mutants suggest that the rifM and -N
gene products act at an early stage of AHBA biosynthesis,
probably in or prior to the formation of aDAHP. The product of
the rifL gene may also be related to the formation of aDAHP,
but it could also or additionally affect the enzymatic activity of
AHBA synthase.
The Nitrogen Source in aDAHP Formation—The available
data do not support the original suggestion that the nitrogen of
AHBA originates from the amide nitrogen of glutamine
through the action of an amidohydrolase, which acts in concert
with a DAHP synthase to generate aDAHP. Therefore, a dif-
ferent source and mode of introduction of the nitrogen must be
identified. The product of the orf9 gene is homologous to pyri-
doxal phosphate (PLP)-dependent transaminases and was sus-
pected to carry out this function of introducing the nitrogen
into a precursor of AHBA. This has been ruled out by the
mutagenesis experiment, which showed no effect of the inacti-
vation of orf9 on rifamycin B production. The fact that the
coexpression of rifG–H, -K–N, and -J resulted in production of
AHBA in S. coelicolor YU105 further suggests that the nitro-
gen-introducing activity must reside on these seven rif genes,
although we cannot exclude the possibility that a protein from
S. coelicolor YU105 has taken over this function. It is worth
noting that the deduced peptide sequence of the AHBA syn-
thase gene (RifK) shows homology to the products of a series of
genes implicated primarily in dehydration/deoxygenation as
well as transamination reactions in deoxysugar biosynthesis
(33). The recombinant AHBA synthase can bind the cofactor
pyridoxamine phosphate as well as PLP, and the PLP form of
the enzyme can be converted to the pyridoxamine phosphate
form by incubation with the amino donor, glutamate.
8 Based on
these observations, it is speculated that the AHBA synthase,
possibly together with the rifL, -M, and/or -N gene products,
may have an additional function to introduce the nitrogen into
an intermediate in AHBA biosynthesis. Consistent with this
hypothesis, no accumulation of aDHS, aDHQ, or their likely
5 R. Mu ¨ller and H. G. Floss, unpublished results.
6 L.-Y. Kuan and T.-W. Yu, unpublished results.
7 T.-W. Yu, D. Hoffmann, D. Clade, E. Zeistner, and H. G. Floss,
unpublished results.
8 T.-W. Yu and C.-G. Kim, unpublished results.
Characterization of the AHBA Biosynthetic Genes 12554aromatization product, protocatechuic acid, was observed in
the rifK mutant of A. mediterranei (33).
9 Plausible scenarios for
such a second function of rifK could involve its joint action with
rifL either to convert a keto group into the corresponding imine
by transamination (RifK) and oxidation (RifL), or to replace a
hydroxy with an amino group by oxidation to the ketone (RifL)
and transamination (RifK).
Pathway of AHBA Formation—The results of this study de-
fine which of the rif biosynthetic genes are necessary for for-
mation of the AHBA starter unit of rifamycin. This sets the
stage for the further definition of the AHBA biosynthetic path-
way at the enzymatic level. The transfer of the ability to pro-
duce AHBA to the heterologous host, S. coelicolor, through the
expression cassette built into vector pHGF7604 also provides
an important tool both for further analysis of the AHBA path-
way and for the heterologous expression of other genes from the
biosynthetic gene clusters of AHBA-derived antibiotics.
The demonstrated involvement of rifG,- H,- J, and -K in
AHBA formation is consistent with and lends credence to the
originally proposed sequence of reactions leading from aDAHP
via aDHQ and aDHS to AHBA (Fig. 1). However, the part of the
original hypothesis dealing with the formation of aDAHP may
require some modification to accommodate a different mode of
nitrogen introduction as well as the requirement for three
additional genes, rifL,- M, and -N, in the pathway. The forma-
tion of aDAHP may involve a very different way of generating
a nitrogen-containing precursor, presumably the imine of ery-
throse 4-phosphate or erythrose, for the condensation reaction
catalyzed by the rifH gene product, one that is mediated by the
action of the RifK–N proteins. Alternatively, the nitrogen may
be introduced at a later stage, again by a process that involves
the action of the rifK–N gene products.
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